All News

With the approval, rituximab has become the first biologic therapy approved by the FDA for PV, and the first major advancement in treatment of the condition in 6 decades.

A new report from the US Centers for Disease Control and Prevention (CDC) has shown that suicide rates are rising in nearly every state.

Half of people who have diabetes eventually develop diabetic peripheral neuropathy, and the warning signs are sensory symptoms that start in the distant periphery and progressing in a characteristic 'glove and stocking' way.

Delayed or failed degree completion is associated with much higher economic consequences for advanced-degree as compared to baccalaureate-degree programs.

Indazole chloride may be able to reduce disability burden in patients with multiple sclerosis by producing good inflammation that promotes axon myelination.

Top news of the day from across the health care landscape

A systematic literature review published in Health Affairs found that Medicaid expansion under the Affordable Care Act (ACA) was associated with increases in coverage, service use, quality of care, and Medicaid spending.

Among HIV-positive women with diabetes, HIV control has improved over time, but diabetes control has not.

An evaluation of the impact of persistence to oral antidiabetic medication on reducing the risk of hospitalization in adult patients with type 2 diabetes.

Point-of-care testing (POTC) increase patients' access to care and treatment. In 2 areas—influenza and streptococcal pharyngitis—POCT is available, but not used as often as it could be.

Kidney disease occurs along a continuum, and for people who have diabetes, the risk of developing kidney disease is significantly elevated.

Should emergency room clinicians use a breath-actuated nebulizer (BAN) or is a metered-dose inhaler (MDI) a better choice?

Although precision medicine holds promise for advanced cancer care, many oncologists indicated challenges in the adoption of new, targeted therapies.

Top news of the day from across the health care landscape.

Trustees for Medicare said that Medicare Part A, which covers hospital bills, will become insolvent in 2026, 3 years earlier than the projection last year in its annual report.

Emicizumab-kxwh is an antibody that activates the natural coagulation process in people with hemophilia A who lack factor VIII.

Upadacitinib is currently being tested in phase 3 trials of rheumatoid arthritis, psoriatic arthritis and Crohn’s disease, and is being investigated to treat ulcerative colitis, ankylosing spondylitis, atopic dermatitis and giant cell arteritis.

Levofloxacin is a fluoroquinolone antibiotic medicine that treats certain bacterial infections, including some types of pneumonia and bronchitis.

Specialty pharmacies play a vital role in the patient journey from diagnosis to treatment.

Top news of the day from across the health care landscape.

Study finds Medicaid expansion associated with increases in coverage, service use, quality of care, and spending.

Esketamine is a glutamate receptor modulator capable of restoring synaptic connections in the brains of patients with depression.

Officials with the FDA have approved Lannett Company’s Levofloxacin Oral Solution.

Top news of the day from across the health care landscape.

The latest teen drug use survey reveals that use of vaping devices and e-liquids have increased.

Data revealed at ASCO shows combination of atezolizumab (Tecentriq), bevacizumab (Avastin), carboplatin, and paclitaxel reduced the risk of death by 22% compared with bevacizumab and chemotherapy.

In a study presented at ASCO, Cemiplimab shows substantial activity and durable responses with an acceptable safety profile in treatment of metastatic cutaneous squamous cell carcinoma.

Pegfilgrastim-jmdb is the first biosimilar to pegfilgrastim (Neulasta) approved by the FDA.

The FDA has approved pegfilgrastim-jmdb (Fulphila, Mylan GmbH) as the first biosimilar to pegfilgrastim (Neulasta) to help reduce the chance of fever-causing infection for a population of patients with cancer.